Table 4.
Self-reported ESAVIs after receiving the first and second dose of any of the available COVID-19 vaccines in Ecuador (n = 6645).
| Self-Reported ESAVIs after COVID-19 Vaccination | First Dose | Second Dose | p Value * | |||
|---|---|---|---|---|---|---|
| n | (%) | n | (%) | |||
| Time of ESAVIs onset | Minutes | 490 | 7.4% | 210 | 3.2% | <0.001 |
| Hours | 3317 | 49.8% | 1325 | 19.9% | ||
| Days | 921 | 13.8% | 463 | 7.0% | ||
| Weeks | 69 | 1.0% | 0,0 | 0.0% | ||
| No side effects | 1857 | 27.9% | 4656 | 70.0% | ||
| Total | 6654 | 100% | 6654 | 100% | ||
| Mild self-reported ESAVIs | Joint pain | 1187 | 7.0% | 437 | 7.4% | 0 |
| Headache | 2570 | 15.2% | 939 | 15.9% | ||
| Muscle pain | 2143 | 12.6% | 761 | 12.9% | ||
| Pain or swelling at the injection site | 3286 | 19.4% | 1219 | 20.7% | ||
| Shaking chills | 1659 | 9.8% | 446 | 7.6% | ||
| Fatigue or tiredness | 2461 | 14.5% | 847 | 14.4% | ||
| Mild/low grade fever (37.1–38 °C) | 1126 | 6.6% | 345 | 5.8% | ||
| General Discomfort | 2029 | 12.0% | 770 | 13.1% | ||
| Gastrointestinal discomfort | 413 | 2.4% | 116 | 2.0% | ||
| Urinary discomfort | 82 | 0.5% | 20 | 0.3% | ||
| Total reports | 16,956 | 100% | 5900 | 100% | ||
| Moderate self-reported ESAVIs | Diarrhea | 296 | 13.1% | 108 | 14.7% | 0 |
| Skin rash | 119 | 5.3% | 40 | 5.4% | ||
| Fever (>38°) | 654 | 29.1% | 175 | 23.8% | ||
| Swollen glands | 279 | 12.4% | 145 | 19.7% | ||
| Nausea | 566 | 25.1% | 165 | 22.4% | ||
| Pruritus | 237 | 10.5% | 64 | 8.7% | ||
| Vomit | 100 | 4.4% | 39 | 5.3% | ||
| Total reports | 2251 | 100% | 736 | 100% | ||
| Severe self-reported ESAVIs | Anaphylaxis | 8 | 2.7% | 1 | 0.7 | 0 |
| Tachycardia | 176 | 59.9% | 81 | 57.9% | ||
| Guillain Barre sd. | 7 | 2.4% | 3 | 2.1% | ||
| Facial swelling | 20 | 6.8% | 6 | 4.3% | ||
| High blood pressure | 55 | 18.7% | 32 | 22.9% | ||
| Transverse myelitis | 2 | 0.7% | 0 | 0.0% | ||
| Facial paralysis | 6 | 2.0% | 5 | 3.6% | ||
| Coagulation disorders | 20 | 6.8% | 12 | 8.6% | ||
| Total reports | 294 | 100% | 140 | 100% | ||
| Measures to mitigate self-reported ESAVIs | Only wait | 2295 | 34.5% | 883 | 13.3% | <0.001 |
| Taking medication | 2929 | 44.0% | 1151 | 17.3% | ||
| Visiting a physician | 319 | 4.8% | 126 | 1.9% | ||
| Hospitalization | 23 | 0.3% | 10 | 0.2% | ||
| No response | 1088 | 16.4% | 4484 | 67.4% | ||
| Total | 6654 | 100% | 6654 | 100% | ||
* The p-value was obtained by Chi-Square test.